Dear Editor, We read with interest Rygard and colleague's [1] "Lowdose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis". While the authors discuss the potential clinical ramifications of their findings, the evidence that corticosteroids reduce the duration of shock and mechanical ventilation also likely has important ramifications for the design of current and future randomized trials evaluating interventions for the treatment of septic shock. A number of randomized clinical trials are underway in which low-dose corticosteroids and adjunctive therapies (i.e., vitamin C) are compared to placebo, with a primary outcome of time to shock resolution or change in SOFA score. Can the authors comment on how their findings regarding shock reversal might inform the design of ongoing septic shock trials, especially where the primary outcome is time to shock resolution or the related outcome of change in SOFA score? If these trials combining corticosteroids and adjunctive therapies demonstrate a significant difference in vasopressor-free days or time to shock reversal, there is limited additional knowledge gained outside of confirming that steroids do indeed reduce time on vasopressors. In light of the authors' findings, should ongoing trials change their control arm to low-dose corticosteroids rather than placebo?
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Reply from Dr. Delaney
Law et al. raise a question regarding current and future trials of adjunctive therapies for patients with septic shock. We advocate that the design of clinical trials incorporate the most up to date information available. The fact that adjunctive corticosteroids do not result in a survival benefit, but are associated with a reduced duration of vasopressor therapy, a reduced duration of mechanical ventilation and a reduced duration of intensive care admission for patients with septic shock [1] should be considered in the design of future clinical trials. For example, investigators attempting to assess the incremental benefit of high-dose vitamin C and thiamine in addition to hydrocortisone in patients with septic shock on reversal of shock would require a control group receiving hydrocortisone to assess whether the addition of vitamin C and thiamine was associated with reduction in duration of vasopressor use. It may be worth noting that 59.6% of patients in the control group in the non-randomised trial of hydrocortisone, vitamin C and thiamine received hydrocortisone as a component of standard care [2] . Most importantly, those designing future clinical trials in this field should consider assessing the effect of adjunctive corticosteroids on patient-centred outcomes as the principal objective of future trials.
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